Norgine Announces Major Investment of £23 Million to Enhance Drug Manufacturing in Wales

Norgine's Significant Investment in Wales: A Boost for Local Manufacturing

Norgine, a prominent European specialty pharmaceutical company, has recently revealed a significant investment of £23 million aimed at enhancing its manufacturing capabilities in Hengoed, Wales. This financial commitment is part of a broader plan which has seen over £50 million allocated to the site since 2022. The investment is a clear indication of Norgine's dedication to innovation and growth within the UK pharmaceutical sector, especially in light of the increasing global challenges surrounding supply chains.

With this latest injection of funds, Norgine aims not only to upgrade its facilities but also to bolster the production and distribution of essential medications across the UK and Europe. The initiative will create 44 new skilled positions, reaffirming the company's commitment to supporting the local workforce. Furthermore, the investment includes enhancements to manufacturing processes that prioritize energy efficiency and improved quality control measures.

Jo Stevens, the Welsh Secretary, emphasized the importance of this investment by recognizing the flourishing biotech sector in Wales. According to her, Norgine's commitment to creating well-paying jobs and developing local talent is a testament to the capabilities of the Welsh workforce. She stated, "This investment from Norgine is a sign of trust in our Welsh workforce and a boost that will propel further advancements."

Saulo Martiniano, Norgine's Chief Operating Officer, underscored the company's belief that every scientific breakthrough should reach the patients in need. He explained, "We are enhancing our Hengoed operations through expanded facilities and improved technologies to ensure we can deliver critical medications efficiently. Our enhancements will contribute to the resilience of the healthcare systems in the UK and Europe."

The £23 million expansion is part of a long-term investment strategy that began in 2022. Over these years, Norgine has been committed to enhancing its operational capacities and pursuing international manufacturing partnerships, including collaborations with Japan. Plans for future investments are already underway, with expectations to create more than 75 permanent jobs in production, quality control, and logistics sectors in Wales.

Norgine's comprehensive production and supply strategies have been meticulously designed to scale alongside market demand, ensuring stable access to medications not only across Europe but also in global markets. With over 60 years of experience in specialized engineering and system design, the company supports the manufacturing of drugs for gastrointestinal, rare, and specialty diseases, utilizing both its own portfolio and selected licensing partners.

Moreover, Norgine is committed to contributing positively to the community through various educational and training initiatives. This includes offering internships to students from Cardiff University and apprenticeship programs in partnership with local colleges, which will help cultivate the next generation of manufacturing talent.

Currently, the Hengoed facility employs more than 600 skilled professionals and produces around 50 million packages of pharmaceuticals and medical products annually. Impressively, the site operates entirely on low-carbon electricity, reflecting Norgine's commitment to sustainable manufacturing while striving for expansion.

In summary, Norgine's recent £23 million investment in Wales not only emphasizes their strategic growth plans but also highlights the importance of local workforce development in the pharmaceutical industry. By enhancing their production capabilities and investing in sustainable practices, Norgine is set to strengthen healthcare access and contribute positively to the community and environment in the years to come.